News
BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
BioTime, Inc., a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen ® for dry-AMD, was presented at the Association for Research in Vision and Ophthalmology meeting taking place from April 29 th– May 3 rd, 2018, in Honolulu, Hawaii. Eyal Banin, the presenting author...
BioTime, Inc., a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen ® for dry-AMD, was presented at the Association for Research in Vision and Ophthalmology meeting taking place from April 29 th– May 3 rd, 2018, in Honolulu, Hawaii. Eyal Banin, the presenting author...